Women experienced infections, scarring, device migration and other complications after a BioZorb marker failed to absorb properly, lawsuit claims.
Breast cancer survivor indicates the chemotherapy tissue marker BioZorb did not absorb back into her body, leaving her with severe pain.
Following pretrial motions for summary judgement, plaintiffs have filed a request to amend their BioZorb implant lawsuit, adding additional details in support of their design defect and failure to warn claims.
Four lawsuits over BioZorb Marker will be selected for early bellwether trials, to help gauge how juries may respond to evidence that the tissue marker caused painful complications.
Five different women joined together to file the lawsuit against BioZorb manufacturer, alleging that the recalled breast tissue markers failed to absorb, fractured or failed, causing painful injuries
